Fernández Javier, Piano Salvatore, Bartoletti Michele, Wey Emmanuel Q
Liver ICU, Liver Unit, Hospital Clinic, University of Barcelona, Barcelona, Spain; European Foundation of Chronic Liver Failure (EF-Clif), Barcelona, Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHED), ISCIII, Spain.
Unit of Internal Medicine and Hepatology, Department of Medicine - DIMED, University of Padova, Padova, Italy.
J Hepatol. 2021 Jul;75 Suppl 1:S101-S117. doi: 10.1016/j.jhep.2020.11.010.
Bacterial infections are frequent in cirrhotic patients with acute decompensation or acute-on-chronic liver failure and can complicate the clinical course. Delayed diagnosis and inappropriate empirical treatments are associated with poor prognosis and increased mortality. Fungal infections are much less frequent, usually nosocomial and associated with extremely high short-term mortality. Early diagnosis and adequate empirical treatment of infections is therefore key in the management of these patients. In recent decades, antibiotic resistance has become a major worldwide problem in patients with cirrhosis, warranting a more complex approach to antibiotic treatment that includes the use of broad-spectrum antibiotics, new administration strategies, novel drugs and de-escalation policies. Herein, we review epidemiological changes, the main types of multidrug-resistant organisms, mechanisms of resistance, new rapid diagnostic tools and currently available therapeutic options for bacterial and fungal infections in cirrhosis.
细菌感染在急性失代偿期肝硬化患者或慢加急性肝衰竭患者中很常见,并且会使临床病程复杂化。诊断延迟和经验性治疗不当与预后不良及死亡率增加有关。真菌感染则要少见得多,通常为医院获得性感染,且与极高的短期死亡率相关。因此,早期诊断和对感染进行充分的经验性治疗是这些患者管理的关键。近几十年来,抗生素耐药性已成为肝硬化患者中一个全球性的主要问题,这就需要采用更复杂的抗生素治疗方法,包括使用广谱抗生素、新的给药策略、新型药物和降阶梯策略。在此,我们综述了肝硬化患者细菌和真菌感染的流行病学变化、主要多重耐药菌类型、耐药机制、新的快速诊断工具以及当前可用的治疗选择。